According to a paper published in the September issue of Retina, The Journal of Retinal and Vitreous Diseases,
a pilot study suggests that the topical nonsteroidal anti-inflammatory
(NSAID) eye drop of Xibrom (bromfenac ophthalmic solution) 0.09%,
administered twice daily may have an additive effect when used with
intravitreal Lucentis (ranibizumab injection) in reducing retinal
thickness in neovascular age-related macular degeneration, or NV AMD.Read more of the company's press release.
No comments:
Post a Comment